Krystal Biotech Inc. to Showcase at Upcoming Scientific Conferences

Krystal Biotech, Inc., a biopharmaceutical company based in Pittsburgh, has announced its participation in several upcoming scientific conferences. The company, which operates within the Health Care sector and focuses on the Biotechnology industry, is known for its proprietary gene therapy platform aimed at treating patients with rare debilitating disorders. Krystal Biotech primarily serves patients in Pennsylvania and is listed on the Nasdaq stock exchange.

As of April 24, 2025, Krystal Biotech’s stock closed at $168.06 USD. Over the past year, the stock has experienced significant fluctuations, reaching a 52-week high of $219.34 USD on July 25, 2024, and a 52-week low of $141.72 USD on January 13, 2025. The company’s market capitalization stands at approximately $4.89 billion USD.

Krystal Biotech’s financial metrics include a price-to-earnings ratio of 56.67 and a price-to-book ratio of 5.04453, reflecting a substantial valuation multiple. These figures highlight the company’s strong market position and investor interest in its innovative gene therapy solutions.

For more information about Krystal Biotech’s activities and upcoming events, interested parties can visit their official website at www.krystalbio.com or follow their stock performance on the Nasdaq.